Pre-Made Sotatercept Biosimilar, Fusion Protein targeting INHBA/ACT fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting EDF/FRP for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Sotatercept Biosimilar, Fusion Protein targeting INHBA/ACT fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting EDF/FRP is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Sotatercept is a fusion protein contains extracellular domain of the human activin receptor type IIA fused with the Fc domain of human IgG1. Sotatercept acts as a ligand trap for members of the TGF-¦Â superfamily, thus restoring balance between the growth-promoting activin growth differentiation factor pathway and the growth-inhibiting BMP pathway. Sotatercept has been used to treat hematologic disorders, dysfunctional TGF-¦Â superfamily signaling pathway based bone loss, chemotherapy-induced anemia, multiple myeloma, myelodysplastic syndromes, ¦Â-thalassemia, and end-stage kidney disease.
| Products Name (INN Index) | Pre-Made Sotatercept Biosimilar, Fusion Protein targeting INHBA/ACT fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting EDF/FRP |
|---|---|
| INN Name | sotatercept |
| Target | INHBA |
| Format | Fusion Protein |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | Fusion – [ACVR2A (activin A receptor type IIA, ActR-II, ActRIIA)]2 – IGHG1 Fc (Fragment constant) |
| VD LC | Fusion – [ACVR2A (activin A receptor type IIA, ActR-II, ActRIIA)]2 – IGHG1 Fc (Fragment constant) |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Celgene?corporation (Summit USA) / Acceleron?Pharma, Inc (Cambridge UK) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | INHBA |
| Package |
